| abstract |
FIELD: chemistry.SUBSTANCE: invention relates to novel phenylaminopyrimidine compounds of formula I, which are JAK kinase inhibitors. In particular, these compounds selectively act on JAK2 kinase. The compounds can be used to treat diseases such as immunological and inflammatory diseases; hyperproliferative diseases, myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases. In the compound of formula I, Q and Z are independently selected from N and CR; Ris independently selected from hydrogen, halogen, R, OR, OH, R, OR, CN, CF, (CH)nN(R), where n equals 1,2 or 3, NO, RR, NRSOR, COR, NRCOR, COH, COR, NRCOR, RCN, ROH, RORand ORR; or two substitutes Rtogether with carbon atoms with which they are bonded form an unsaturated 5- or 6-member heterocyclic ring containing 1-4 N atoms; Ris Calkyl; Ris R, Calkenyl or phenyl; Ris NH, NHR, N(R), substituted or unsubstituted morpholine, CHmorpholine, substituted or unsubstituted thiomorpholine, substituted or unsubstituted thiomorpholino-1-oxide, substituted or unsubstituted thiomorpholino-1,1-dioxide, substituted or unsubstituted piperazinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted imidazolyl, substituted or tetrahydrofuranyl unsubstituted and substituted or unsubstituted tetrahydropyranyl; Ris Calkylene; R-Rare independently selected from H, RCN, halogen, substituted or unsubstituted Calkyl, OR, COR, N(R), NOand CON(R), wherein at least one of R-Ris RCN; the rest of the values of the radicals are given in the claim.EFFECT: high efficiency of treatment.29 cl, 7 dwg, 2 tbl, 93 ex |